ALBI grade predicts suitability for further systemic therapy following sorafenib in patients with advanced hepatocellular carcinoma

Liver cancer international Pub Date : 2022-11-01 DOI:10.1002/lci2.61

Omar Fakih, Suraiya S. Haddad, Sophie Walker, Julien Edeline, Florien Estrade, Xin Wang, Angela Lamarca, Mairéad G. McNamara, Juan W. Valle, Richard A. Hubner

{"title":"ALBI grade predicts suitability for further systemic therapy following sorafenib in patients with advanced hepatocellular carcinoma","authors":"Omar Fakih, Suraiya S. Haddad, Sophie Walker, Julien Edeline, Florien Estrade, Xin Wang, Angela Lamarca, Mairéad G. McNamara, Juan W. Valle, Richard A. Hubner","doi":"10.1002/lci2.61","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background & Aims</h3>\n \n <p>Preserved performance status (PS) and liver function are required for systemic therapy in patients with advanced hepatocellular carcinoma (aHCC). We investigated the frequency of suitability for further systemic therapies following sorafenib in aHCC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Demographic, tumour and therapy-related data were collected retrospectively for patients with aHCC who received sorafenib at a UK tertiary referral centre (training cohort), and an independent French centre (validation cohort). The primary endpoint was percentage of patients with Child-Pugh class A (CP-A) liver disease and PS 0–1 after sorafenib discontinuation.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Sorafenib was received by 182 patients. After sorafenib discontinuation, 93 patients (51%) were CP-A and 60 patients (33%) were PS 0–1; 43 patients (24%) were both CP-A and PS 0–1. On multivariable analysis, patients with Albumin-Bilirubin (ALBI) score of 1 at time of sorafenib commencement were more likely to be suitable for post-sorafenib therapy, (44% grade 1 vs 15% grade 2) (OR 3.76, 95%CI 1.72–8.25, <i>P</i> = .0009). In the validation cohort of 216 patients baseline ALBI grade was also significantly associated with suitability for further systemic therapy (<i>P</i> = .008).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Most patients with aHCC are not suitable for further systemic therapy after sorafenib, but those with ALBI grade 1 have a greater likelihood of suitability.</p>\n </section>\n </div>","PeriodicalId":93331,"journal":{"name":"Liver cancer international","volume":"4 1","pages":"5-12"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/lci2.61","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver cancer international","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lci2.61","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background & Aims

Preserved performance status (PS) and liver function are required for systemic therapy in patients with advanced hepatocellular carcinoma (aHCC). We investigated the frequency of suitability for further systemic therapies following sorafenib in aHCC.

Methods

Demographic, tumour and therapy-related data were collected retrospectively for patients with aHCC who received sorafenib at a UK tertiary referral centre (training cohort), and an independent French centre (validation cohort). The primary endpoint was percentage of patients with Child-Pugh class A (CP-A) liver disease and PS 0–1 after sorafenib discontinuation.

Results

Sorafenib was received by 182 patients. After sorafenib discontinuation, 93 patients (51%) were CP-A and 60 patients (33%) were PS 0–1; 43 patients (24%) were both CP-A and PS 0–1. On multivariable analysis, patients with Albumin-Bilirubin (ALBI) score of 1 at time of sorafenib commencement were more likely to be suitable for post-sorafenib therapy, (44% grade 1 vs 15% grade 2) (OR 3.76, 95%CI 1.72–8.25, P = .0009). In the validation cohort of 216 patients baseline ALBI grade was also significantly associated with suitability for further systemic therapy (P = .008).

Conclusions

Most patients with aHCC are not suitable for further systemic therapy after sorafenib, but those with ALBI grade 1 have a greater likelihood of suitability.

Abstract Image